Developmental funds have been used for two purposes during the last grant cycle and we propose to continue funding in these areas in the next grant cycle. 1) Pilot Funds - The CCSG developmental funds support three types of pilot grants, each targeting a different Cancer Center member group: ? Push grants - to accelerate (or """"""""push"""""""") the pace of effort on cancer-focused research initiatives judged to have a high potential to lead to peer-reviewed funding within 1 -2 years. Pull grants - to encourage cancer research among non-cancer members and new members, i.e. to """"""""puir them into the Cancer Center. Paff/7er grants - to encourage clinicians to partner with a basic or population scientist in a joint project in translational research. Partner grants require matching funds from the clinical department. These pilot grants have yielded a return of investment of about 14 fold over the past five years. We plan to continue using these pilot project mechanisms in the next grant cycle. 2) Shared Resource Development - We have used CCSG developmental funds from the past grant cycle to support our Crystallography and Computational Biosciences (CCB) shared resource. This shared resource was originally proposed in our last competing renewal and is now requested as a full shared resource. In the new grant cycle, we propose funding for two developing shared resources: Synthetic Chemistry and Translational Imaging. In addition to continuing funding for these two areas, we propose adding bridge funding support in the next grant cycle.
Developmental funds provide a key source of support for the strategic and programmatic priorities and scientific opportunities of our Center as identified through our planning and evaluation processes. These funds provide the opportunity to explore innovative pilot projects, new collaborations and new technologies.
|Dutta, Samrat; Rivetti, Claudio; Gassman, Natalie R et al. (2018) Analysis of single, cisplatin-induced DNA bends by atomic force microscopy and simulations. J Mol Recognit 31:e2731|
|Paek, M-S; Nightingale, C L; Tooze, J A et al. (2018) Contextual and stress process factors associated with head and neck cancer caregivers' physical and psychological well-being. Eur J Cancer Care (Engl) 27:e12833|
|Atkins, Hannah M; Appt, Susan E; Taylor, Robert N et al. (2018) Systemic Iron Deficiency in a Nonhuman Primate Model of Endometriosis. Comp Med 68:298-307|
|Pardee, Timothy S; Anderson, Rebecca G; Pladna, Kristin M et al. (2018) A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clin Cancer Res 24:2060-2073|
|Yang, M; Forbes, M E; Bitting, R L et al. (2018) Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system? Ann Oncol 29:311-323|
|Godwin, Ryan C; Gmeiner, William H; Salsbury Jr, Freddie R (2018) All-atom molecular dynamics comparison of disease-associated zinc fingers. J Biomol Struct Dyn 36:2581-2594|
|Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877|
|Votanopoulos, Konstantinos Ioannis; Bartlett, David; Moran, Brendan et al. (2018) PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol 25:674-678|
|Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208|
|Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307|
Showing the most recent 10 out of 548 publications